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Acute myeloid leukemia (AML) is an aggressive and
lethal blood cancer maintained by rare populations
of leukemia stem cells (LSCs). Selective targeting of
LSCs is a promising approach for treating AML and
preventing relapse following chemotherapy, and
developing such therapeutic modalities is a key pri-
ority. Here, we show that targeting telomerase activ-
ity eradicates AML LSCs. Genetic deletion of the telo-
merase subunit Terc in a retroviral mouse AMLmodel
induces cell-cycle arrest and apoptosis of LSCs, and
depletion of telomerase-deficient LSCs is partially
rescued by p53 knockdown. Murine Terc/ LSCs
express a specific gene expression signature that
can be identified in human AML patient cohorts and
is positively correlated with patient survival following
chemotherapy. In xenografts of primary human AML,
genetic or pharmacological inhibition of telomerase
targets LSCs, impairs leukemia progression, and de-
lays relapse following chemotherapy. Altogether,
these results establish telomerase inhibition as an
effective strategy for eliminating AML LSCs.
INTRODUCTION
Acute myeloid leukemia (AML) is a highly prevalent and lethal
blood cancer. The 5-year overall survival is less than 45% for pa-
tients below 60 years old and less than 10% for patients older
than 60 (Szer, 2012). Leukemia stem cells (LSCs) are key medi-
ators for chemotherapy resistance and relapse in AML (GentlesCellet al., 2010; Ishikawa et al., 2007). LSCs are defined functionally
by having the ability to initiate, maintain, and serially propagate
AML and differentiate into committed progeny that lack this
ability (Bonnet and Dick, 1997; Krivtsov et al., 2006; Lane and
Gilliland, 2010). Therefore, depleting LSCs represents a key
therapeutic strategy for preventing relapse and improving the
long-term outcomes of AML therapy.
LSCs possess limitless self-renewal that is engendered
by oncogenic activation of numerous pathways, including the
HoxA cluster (Krivtsov et al., 2006), Wnt-b-catenin (Heidel
et al., 2012;Wang et al., 2010), or telomerase activation (Gessner
et al., 2010). The telomerase holoenzyme consists of a reverse
transcriptase subunit (TERT), an RNA template subunit (TERC),
and a protective shelterin scaffold. In the absence of telomerase
activity and alternative telomere lengthening pathways, cellular
division results in the loss of telomere sequences, telomere un-
capping, and the activation of cellular checkpoints that are
similar to those induced by DNA double-stranded breaks (Celli
and de Lange, 2005; Okamoto et al., 2013).
Many human cancers, including AML, are characterized by
robust telomerase activity and shortened telomeres relative to
the normal cellular counterpart (Aalbers et al., 2013; Bernard
et al., 2009; Drummond et al., 2005; Gessner et al., 2010), and
a requirement of telomerase has recently been described for
the development of chronic myeloid leukemia induced by
BCR-ABL (Vicente-Duen˜as et al., 2012). These findings have
identified telomerase as a potential therapeutic target in cancer
and motivated the development of telomerase inhibitors. The
13-mer antisense oligonucleotide imetelstat (Geron Corporation)
is a competitive inhibitor that binds to the RNA template (TERC)
of the telomerase holoenzyme and has shown in vitro efficacy in
a number of tumor models (Herbert et al., 2005). Imetelstat has
recently entered clinical trials for the treatment of myeloprolifer-
ative neoplasms with remarkable efficacy (Tefferi et al., 2013,Stem Cell 15, 775–790, December 4, 2014 ª2014 Elsevier Inc. 775
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telomerase have been described in patients with AML (Aalbers
et al., 2013; Calado et al., 2009), and constitutional marrow
failure associated with genetic telomeropathies has a high risk
of developing leukemias (Kirwan and Dokal, 2008), suggesting
that telomere shortening may also predispose to malignancy.
Targeting AML LSCs through telomerase inhibition is an
attractive proposition; however, it has not yet been determined
whether telomerase inhibition is effective in LSCs. Moreover,
telomerase inhibition could potentially cause further genomic
instability and increased mutagenesis, allowing the emergence
of adaptive changes (Hu et al., 2012). To determine whether
telomerase is required for AML LSC function, we performed
functional LSC analysis in well-characterized murine models
of AML in the presence or absence of telomerase. Furthermore,
using xenograft transplantation assays, we examined the ef-
fects of genetic and pharmacological inhibition of telomerase
in human AML in vivo. This study provides strong evidence
that telomerase is essential for the maintenance of LSC function
and identifies the modulation of telomerase as an LSC-specific
therapy.
RESULTS
Telomerase Deficiency Impairs In Vitro Self-Renewal
and Delays AML Onset in Murine AML
In order to determine the role of telomerase on AML cell function,
bone marrow (BM) LKS+ cells from either G3 Terc/ or WT do-
nors were transformed with a retroviral MLL-AF9 construct (Fig-
ure 1A). Reduced telomere length was confirmed in Terc/ in
comparison to WT MLL-AF9 cells (Figures S1A–S1C available
online). Moreover, MLL-AF9 transformation increased telome-
rase activity and reduced telomere length (Figures S1D and
S1E). In vitro colony-forming assays revealed reduced colony
numbers in Terc/ in comparison to WT MLL-AF9 cells and
complete absence of colonies in the Terc/ condition after
seven passages (Figure 1B). Terc/ AML colonies were charac-
teristically smaller in comparison to wild-type (WT) AML (Fig-
ure 1C). These findings suggest that telomerase deficiency leads
to the gradual loss of AML cells in vitro.
In order to determine the role of telomerase for AML in vivo,
equal numbers of WT or Terc/ MLL-AF9-transformed LKS+
were transplanted into syngeneic WT recipients. In both WT
and Terc/, AML developed with full penetrance; however,
Terc/ AML displayed delayed latency (Figure 1D). Thirty days
after transplantation, peripheral blood (PB) white cell count
(WCC), BM WCC, spleen weight, and spleen cellularity were
lower in Terc/ in comparison to WT AML recipients (Figures
1E–1H, left). At individual disease onset, the AML phenotype
and disease burden were similar between WT and Terc/ con-
ditions (Figures 1E—1H, right), and spleenweight andWCCwere
found to be higher in Terc/ AML, most likely reflecting the
longer duration of disease (Figures 1F and 1G, right). These find-
ings demonstrate that telomerase deficiency delays the onset of
leukemia but is not essentially required for the initiation of AML
in vivo.
To validate these findings in other subtypes of AML, G3
Terc/ or WT cells were transformed with AML1-ETO/
KRASG12C (Chou et al., 2011; Zhao et al., 2014), CDX2 (Scholl776 Cell Stem Cell 15, 775–790, December 4, 2014 ª2014 Elsevier Inet al., 2007), or BCR-ABL/NUP98-HOXA9 (Dash et al., 2002).
AML1-ETO/KRASG12C Terc/ AML had prolonged survival,
and all Terc/ AMLs showed reduced disease burden and
impaired in vivo expansion of AML (Figures 1I–1J and S1F–S1K).
Telomerase Deficiency Eradicates Functional LSCs in
Murine AML
In vivo serial transplantation represents the gold standard for the
analysis of long-term LSC function. Therefore, we isolated viable
AML cells from leukemic WT or Terc/ mice (GFP+, Sytox
Blue) and transplanted these cells into syngeneic irradiated
secondary recipients (Figure 2A). All WT AML recipients devel-
oped AML with rapid onset, whereas secondary recipients of
Terc/ AML cells rarely developed AML (Figure 2B). Terc/
AML secondary recipients showed fewer GFP+ cells (Figure 2C)
and leukemic blasts in PB, spleen, and liver (Figure 2D). Consis-
tent with these findings, other parameters of AML severity
were also reduced; e.g., spleen size, weight, splenic AML cell
engraftment, BM AML cell engraftment, PB WCC, and circu-
lating AML cells (Figures S2A–S2F). Using the MLL-AF9 model,
we determined with in vivo limiting dilution analysis that the
LSC frequency in Terc/ AML was 1:224,000 in comparison
to 1:184 in WT AML, representing a reduction of greater than
1,000-fold (Figures 2E and 2F). LSC frequency (LinnegGFP+
KithighCD34+FcGR+; Figure 2G) (Krivtsov et al., 2009) was similar
between primary WT and Terc/ MLL-AF9 LKS+ recipients,
demonstrating that genetic perturbation of telomerase compro-
mises LSC function without preventing the initial generation of
LSCs (Figure 2H). Finally, limiting dilution analysis of purified
LSCs confirmed the observed loss of function in Terc/ versus
WT LSCs (Figures 2I and 2J). LSC frequency was markedly
reduced in Terc/ AML1-ETO/KRASG12C AML and Terc/
BCR-ABL/NUP98-HOXA9 AML in comparison to WT controls
(Figures S2G, S2H, and S2K). Furthermore, secondary trans-
plantation of Terc/ AML1-ETO/KRASG12C AML or Terc/
BCR-ABL/NUP98-HOXA9 AML demonstrated prolonged sur-
vival and diminished AML expansion in comparison to WT con-
trols (Figures S2I, S2J, S2L, and S2M).
Telomerase Deficiency in LSCs Is Associated with
Cell-Cycle Arrest, p53 Activation, and Programmed
Cell Death
To gain insights into the mechanisms underlying the susceptibil-
ities of Terc/ LSCs in vivo, we performed transcriptional
profiling of purified Terc/ and WT LSCs from leukemic primary
recipients. One hundred and forty probe sets were differentially
expressed between Terc/ and WT LSCs (with a p value cutoff
of 0.001; Figure 3A). These expression changes predicted
abnormal cell-cycle and aberrant DNA replication, recombina-
tion, and repair, including homologous recombination, altered
cell morphology, cellular function and maintenance, and acti-
vated programmed cell death in Terc/ LSC in comparison to
WT LSC (Figure 3B). The expression of MLL-AF9 binding targets
was unchanged (data not shown). Flow cytometric analysis of
WT and Terc/ LSCs confirmed cell-cycle abnormalities with
an increased proportion of Terc/ LSC remaining in G1 phase
followed by a concomitant reduction in S/G2/M phases in com-
parison to WT LSC (Figures 3C–3F). To identify transcription fac-
tor candidates that could mediate the observed cellular defects,c.
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Figure 1. Telomerase Deficiency Impairs In Vitro Self-Renewal and Delays AML Onset
(A) Experimental scheme. BM LKS+ cells were isolated from WT or G3 Terc/ mice, transduced with MLL-AF9-GFP retrovirus in vitro in order to generate
leukemia stem cells (LSCs) and plated into methylcellulose or transplanted into irradiated recipient mice.
(B) Colony-forming assay ofWT (black bars) or Terc/MLL-AF9 LSCs (red bars). Values represent colony-forming unit frequencies ± SE, calculated as number of
colonies per input cells (%). Statistically significant differences according to Student’s t test; *p < 0.05; **p < 0.01; n = 3.
(C) Week 5 WT and Terc/ MLL-AF9 LSC colony morphology.
(D) Median survival was 45 versus 64 days posttransplant for recipients of WT (black line) and Terc/ (red line) MLL-AF9 LSCs, respectively, p = 0.0018, Mantel-
Cox test; n = 5.
(E–H) PBWCC (E), spleen weight (F), spleenWCC (G), and BMWCC (H) from recipients of WT (black) or Terc/ (red) MLL-AF9 LSCs 30 days posttransplant (left)
and again at the onset of AML (right). Each point represents an individual animal and the black line represents themean. p values calculated by Student’s t test and
are representative of two to three independent experiments.
(I and J) Survival (I) and PB WCC (J) of mice injected with WT or Terc/ Aml1Eto + KrasG12C AML; n= 5 per group.
See also Figure S1.
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Telomerase Is a Target for Leukemia Stem Cellswe performed upstream regulator analysis and found activation
of key transcription factors such as p53, p107, and p16/p19,
along with inhibition of E2f1, p65, and Ep400 (Figure 3G). Terc/
LSCs exhibited marked chromosomal instability with end-to-
end chromosomal fusions that were not seen in WT LSCs
(Figure S3A). Western blot analyses on phosphorylated p53Cell(Ser15) and phosphorylated FoxO3a (Ser253) suggested a
clonal dichotomy in Terc/ LSCs regarding p53 regulation
(Figure S3B), showing only minor overlay between the up-
stream regulators identified (Figure S3C), although activation of
p53 signaling was predicted in both independent Terc/ LSC
clones (Figure S3D). Interestingly, downstream p53 target geneStem Cell 15, 775–790, December 4, 2014 ª2014 Elsevier Inc. 777
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Figure 2. Telomerase Deficiency Eradicates Functional LSCs in Murine AML
(A) Experimental scheme. AML cells (viable GFP+ from BM) were isolated from primary recipients at disease onset and injected into secondary recipients.
(B) Median survival was 28 days posttransplant of 20,000 WT AML cells versus not reached for Terc/ AML (followup > 280 days). p = 0.0024, Mantel-Cox test;
n = 5 from two independent experiments.
(legend continued on next page)
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clones, although differential regulation of some additional p53
targets was identified (Figure S3E). The p53 regulatory networks
were enriched in the ATR/ATM signaling pathway modeling acti-
vated ATR and inhibited ATM signaling, which links activated
p53 signaling with the inhibition of homologous recombination,
G1 and S phase arrest, and apoptosis (Figure S3F).
Telomerase Deficiency-Mediated Loss of LSCs Is p53
Dependent
The upstream regulator analysis above revealed p53 as a top
candidate mediating the detrimental effects of telomerase inhibi-
tion on LSC function. To functionally validate this, we depleted
p53 in WT or Terc/ LSCs with a retroviral small hairpin RNA
(shRNA) construct (Dickins et al., 2005). Primary WT or Terc/
MLL-AF9 LKS+ cells were transfected with p53.shRNA or non-
targeting (sh-luc) control. Knockdown of p53 in Terc/ LSCs
resulted in partial rescue of colony-forming capacity in vitro (Fig-
ure 4A), although this was insufficient to rescue the detrimental
effects of telomerase deficiency during late in vitro passage (Fig-
ure S4A). Terc/ LSCs exhibited increased apoptosis in com-
parison to WT cells, and this was partially prevented by p53
knockdown (Figures 4B and 4C). LSC function is greatly enriched
in Kit+Gr1low AML stem cells in comparison to KitlowGr1high-
differentiated AML cells (Wang et al., 2010). Telomerase defi-
cient LSCs had higher Gr1 expression (Figures 4D and 4E) and
reduced Kit expression (Figure 4F), demonstrating enforced dif-
ferentiation of Terc/ in comparison toWT LSCs. Knockdown of
p53 resulted in complete rescue of Kit expression and partial
rescue of Gr1 expression in Terc/ LSC (Figures 4D–4F).
To investigate the functional significance of p53 activation in
Terc/ AML, we transplanted sh-p53.MLL-AF9 LKS+ from WT
or Terc/ mice. As a control, sh-luc.MLL-AF9 LKS+ from WT
or G3 Terc/ mice were also transplanted. Concordant with
the in vitro results, sh-p53 Terc/ AML exhibited increased Kit
expression and enrichment for LSC frequency (Figure 4G and
4H). Functionally, G3 Terc/ sh-p53.MLL-AF9 LKS+ showed
accelerated disease onset in comparison to sh-luc.MLL-AF9
control. We have observed some variegation in telomere lengths
between cohorts of G3 Terc/ mice, so this experiment was
repeated with G3 Terc/ mice demonstrating the shortest
telomeres (Terc-sh-luc* and Terc-sh-p53*; Figure S4B). AML
initiation was significantly impaired in Terc-sh-luc* cells, and,
conversely, Terc-sh-p53* had markedly accelerated disease
onset (Figure 4I). These data demonstrate that the detrimental ef-
fects of telomerase loss on LSC function are telomere length and
p53 dependent. Finally, in serial transplantation, sh-p53 was(C) Engraftment of BM-derived WT (black) or Terc/ AML cells (red) 28 days po
animal). The calculated mean is displayed. p < 0.0001, Student’s t test; n = 18 fr
(D) Histologic analysis of PB, spleen, and liver morphology in WT and Terc/ AM
(E and F) Limiting dilution analysis of WT (E) versus Terc/ MLL-AF9 (F) LSC freq
(red), or 100,000 (black) viable AML cells (Sytox and GFP+); n = 5. LSC freque
Terc/ AML (95% confidence interval, 1:56,000–892,000). p = 0.0001 with Pois
(G) Gating strategy for LSCs with FACS and LinlowGFP+Kit+FcGR+CD34+.
(H) LSC frequency in the BM from primary recipients injected with WT (black s
n = 7–10 from three independent experiments.
(I and J) Limiting dilution analysis of WT (I) or Terc/MLL-AF9 (J) LSCs in seconda
viable LSC (LinlowGFP+Kit+FcGR+); n = 5.
See also Figure S2.
Cellable to completely rescue LSC function in Terc/ LSCs with
the longer telomeres (Figures S4B and S4C).
These data demonstrate that p53 is required for the detri-
mental effects of telomerase deficiency on LSCs; however, addi-
tional pathways may also act to constrain LSC function in the
context of dysfunctional telomerase.
Telomerase-Deficient LSCs Undergo Genetic Crisis and
Apoptosis after Enforced Cell-Cycle Progression
To investigate the cellular mechanisms underlying the observed
impaired function of Terc/ LSCs, we examined the initial
engraftment potential and subsequent cell-fate decisions during
secondary transplantation (Figure 5A). Homing efficiencies were
similar between WT and Terc/ LSCs (Figures 5B and 5C), and,
although there were no differences in early expansion of 100,000
WT and Terc/ LSCs (Figures 5D and 5E), rapid onset of AML
occurred only in the WT, but not Terc/, condition (Figures 2E
and 2F). Terc/ LSC engraftment progressively decreased,
demonstrating that Terc/ LSCs are severely limited in their
ability to expand after enforced replicative stress (Figures 5E,
S2J, and S2M). Cell-cycle analysis revealed fewer quiescent
and G1 Terc/ LSCs with concordant increase in S/G2/M
phases in comparison to WT LSCs (Figures 5F–5I). Critically
shortened telomeres have been associated with chromosomal
instability and the activation of DNA damage. Consistent with
this, phosphorylation of the histone variant H2AX as a sensitive
marker for DNA double-stranded breaks was increased in
Terc/ in comparison to WT LSC (Figures 5J and 5K), and
end-to-end chromosomal fusions were seen only in Terc/
LSCs (Figure S3A). Terc/ LSCs also showed extensive
apoptosis (Figures 5L and 5M). In contrast to these detrimental
effects of telomerase deficiency on LSC fate, we observed rela-
tive preservation of normal LT-HSC and a quantitative but stable
reduction in normal LT-HSC function (Figures S5A and S5B).
Altogether, these data demonstrate depletion of functional
LSCs through dysfunctional telomeres driving chromosomal
instability, DNA damage, and apoptosis upon enforced replica-
tive stress, thereby preventing AML progression in vivo.
A Telomerase-Deficient Gene Signature Predicts
Outcome in Human AML
To determine the role of telomerase in human AML, we examined
TERT expression in human AML subtypes versus normal con-
trols. TERT was highly overexpressed in human AML subtypes,
including AML with t(8;21), AML with inv(16), acute promyelo-
cytic leukemia, and AMLwithmixed-lineage leukemia rearrange-
ments (Figure 6A) (Bagger et al., 2012). Next, we sought tosttransplant (absolute GFP+ cells in both femurs and tibiae in each individual
om three independent experiments.
L 28 days posttransplant.
uency in secondary transplants injected with 100 (blue), 1,000 (purple), 10,000
ncy was 1:184 for WT (95% confidence interval, 1:56–609) and 1:224,000 for
son analysis.
ymbols) or Terc/ MLL-AF9 transformed LKS+ (red symbols) at AML onset;
ry transplants injected with 20 (blue), 200 (purple), 2,000 (red), or 20,000 (black)
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merase-deficient LSCs could be identified in distinct subgroups
of human AML. We used the top 140 differentially expressed
genes between Terc/ and WT LSCs and identified the human
homologs of these genes in order to perform unsupervised hier-
archical clustering analysis of a large, defined cohort of human
AML (Figure 6B; data not shown). Five distinct clusters could
be identified, and one of these clusters showed a particularly
adverse patient outcome after standard chemotherapy (Fig-
ure 6C). The adverse prognosis cluster exhibited fewer cases
of cytogenetically normal (CN; intermediate prognosis) AML
with a trend to more complex karyotype (adverse prognosis)
samples (p = 0.07; Figures 6D and S6–S7D). Therefore, these re-
sults were tested and validated in a second independent data set
comprising exclusively CN AML (Figure 6E) (Metzeler et al.,
2011). To find the key genes that were responsible for driving
these prognostic differences, we used random forest modeling
in order to identify a short list of 40 genes with a significant
impact on survival and then tested the impact of these genes
individually on prognosis. These genes were preferentially found
in pathways regulating DNA damage, replication, and repair (Fig-
ure S6E). We identified five genes (SMC4, CPD, MRC1, SLC2A1,
and SLC44A2) that individually predicted survival in human AML.
Interestingly, the expression profiles resembling telomerase
deficiency were correlated with favorable prognosis (Figure 6F).
In summary, the correlation analyses performed have identified a
telomerase-deficient gene signature consisting of five AML sur-
vival candidates predicting favorable outcome in AML.
Genetic Telomerase Deficiency Impairs Human AML
LSC Function
The data from the murine AML models described above identi-
fied telomerase as a bona fide target for depleting LSCs in vivo.
To confirm these findings in human AML, we examined the ef-
fects of genetic and pharmacological telomerase depletion in
AML cell lines and primary human AML samples. Initially, we
investigated the genetic perturbation of telomerase with short
hairpins targeting the enzymatic subunit TERT in the MLL-AF9
containing human AML cell line Monomac6 (MM6). Reduced
levels of TERT were confirmed at the transcript and protein level
with two independent shRNA constructs (Figures S6F and S6G).
TERT knockdown correlated with reduced AML cell growth
in vitro (Figure 6G). Then, we performed xenograft transplanta-
tion experiments in order to determine the effect of telomerase
insufficiency on human AML cell growth in vivo. Equivalent cell
numbers from nontransduced, nontargeting shRNA control or
TERT-shRNA-transduced MM6 cells were transplanted into irra-Figure 3. Telomerase Deficiency in LSCs Is Associated with Cell-Cycle
(A) Unsupervised hierarchical clustering heatmap displaying differentially expre
higher gene expression (upregulation), and blue zones represent lower gene exp
(B) Cellular functions were predicted on the basis of the overlap of differentially
calculated Z score, and preselected on p < 0.01. Blue represents predicted inhibi
category in Terc/ versus WT condition.
(C) Representative cell-cycle analysis of BM WT or Terc/ LSC with Ki-67 and H
(D–F) Quantification of G1 (D), S/G2/M (E), and G0 (quiescent; F) cell-cycle phas
experiments).
(G) Activation and inhibition of upstream regulators predictedwith IPA. The upstrea
p value for overlay (p < 0.01). Red symbolizes predicted activation, and blue sym
See also Figure S3.
Celldiated NOD.Cg-Prkdcscid Il2rgtm1Wjl Tg(CMV-IL3,CSF2,KITLG)
1Eav/MloySzJ (NSGS) recipients (Wunderlich et al., 2010). The
expansion of MM6 cells was significantly reduced in both
TERT-shRNA conditions in comparison to nontargeting and
nontransduced control conditions as determined by the analysis
of hCD45+ cells in the peripheral blood (Figure 6H) and hematox-
ylin and eosin (H&E) staining of spleen sections (Figure S6H).
Concordant with the primary murine data, we observed a signif-
icant increase of apoptotic MM6 cells and loss of G0/G1 cell-cy-
cle phases in both TERT-shRNA conditions in comparison to
controls (Figures 6I and S6I–S6K). Finally, TERT knockdown
was correlated with increased survival of MM6:NSGS xenografts
in comparison to controls (Figure 6J). These data demonstrate
that genetic perturbation of telomerase is detrimental for human
AML.
Pharmacological Targeting of Telomerase Impairs
Human AML LSC Function and Prolongs Survival in
Primary AML Xenografts
In order to investigate whether pharmacologic inhibition of
telomerase could serve as therapeutic strategy in AML, we
obtained imetelstat (Geron Corporation), an antisense oligonu-
cleotide that specifically targets the RNA component of the
telomerase complex. For optimal translational relevance, we
examined the efficacy of imetelstat on a primary AML patient
sample containing the MLL-AF9 oncogene with the NSGS xeno-
graft model. AML engraftment was confirmed by flow cytometry
prior to the commencement of imetelstat therapy and found to
be similar between groups. Subsequent administration of imetel-
stat prevented the in vivo expansion of AML cells, and ongoing
therapy prevented the development of AML when compared to
vehicle-treated xenografts (Figure 7A). All vehicle-treated xeno-
grafts succumbed to disease at 12 weeks posttransplant when
AML engraftment in peripheral blood had reached 60%.
Reduced engraftment of AML remained significant even 5 weeks
after imetelstat treatment had been suspended. All imetelstat-
treated mice eventually progressed after the cessation of
treatment with a rising human AML cell frequency in peripheral
blood and visible signs of leukemia (Figure 7B). Imetelstat
treatment was associatedwith prolonged overall survival in com-
parison to vehicle control (Figure 7B). Notably, imetelstat was
also able to prevent the expansion of primary patient derived
AML xenografts in an additional three samples tested, demon-
strating the broad applicability of this therapeutic strategy (Fig-
ures 7C–7F and S7A; Table S1).
Next, we examined the effect of imetelstat on LSCs in vivo.
All samples exhibited significant reduction in G0 cell cycle,Arrest, p53 Activation, and Programmed Cell Death
ssed genes (p < 0.001) comparing Terc/ versus WT LSCs. Red represents
ression (downregulation).
expressed genes with ingenuity pathway analysis (IPA), ranked based on the
tion, and red represents predicted activation of the respective cellular function
oechst in order to discriminate G0, G1, and S/G2/M phases.
es in LSCs at AML onset (primary recipients, n = 6–7 from three independent
m regulatorswere ranked based onZ score and preselected on the basis of the
bolizes predicted inhibition of the upstream regulator.
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Figure 4. Telomerase Deficiency-Mediated Loss of LSCs Is p53 Dependent
WT and Terc/ MLL-AF9 LSCs were transduced with shRNA targeting p53 (sh-p53) or luciferase control (sh-luc).
(A) Colony-forming assay of WT sh-luc (black), WT shp53 (blue), terc-sh-luc (red), and terc-sh-p53 (purple) during passage five. Number of colonies per input
cells (%).
(B) Representative flow cytometric analysis of LSC apoptosis (LinKithighannexin V+).
(C) Quantification of apoptotic LSCs.
(D) Representative flow cytometric analysis of LSCs (Kithigh) versus differentiated cells (Grhigh).
(E and F) Median fluorescent intensity of Gr1 (E) and Kit (F).
(G and H) Representative flow cytometry plots (G) and quantification of LSCs (LinKithigh) from BM of primary recipients injected with WT or Terc/ LSCs
transduced with sh-p53 or sh-luc. Mean ± SE; n = 3 from two independent experiments. Statistical significance was determined by Student’s t test.
(I) Survival analysis. Asterisks denote G3 cohorts with the shortest telomeres. Median survival was 34 (WT-sh-luc), 34 (WT-sh-p53), 56 (Terc-sh-luc), 48 (Terc-sh-
p53), undefined (Terc-sh-luc*), and 187.5 (Terc-sh-p53*) days. Terc-sh-luc versus Terc-sh-p53: p = 0.1396; Terc-sh-luc* versus Terc-sh-p53*: p = 0.0404
according to Mantel-Cox test; n = 3–8.
See also Figure S4.
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Telomerase Is a Target for Leukemia Stem Cellsconsistent with enforced cell-cycle entry or failure to re-enter
quiescence (Figures 7G and S7D–S8F) and increased DNA dam-
age (Figures S7B and S7C). In AML-16 (normal cytogenetics
sample), we observed a significant reduction in the phenotypic782 Cell Stem Cell 15, 775–790, December 4, 2014 ª2014 Elsevier InLSC population (CD38low) and increase in differentiated blasts
(CD38high; Figures 7H–7J). Concordant with these findings, we
observed a significant delay in the engraftment and proliferation
of AML cells in secondary recipients, and ongoing imetelstatc.
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Figure 5. Telomerase-Deficient LSCs Undergo Genetic Crisis and Apoptosis after Enforced Cell-Cycle Progression
(A) Experimental scheme. Animals were analyzed 16 hr posttransplant in order to study homing efficiency or at 3 weeks posttransplant for cell-fate analysis.
(B andC) Representative flow cytometry (B) and quantification (C) of 16 hr GFP+ percentage engraftment in total BM from both femurs and tibiae of each individual
sample from WT (black) or Terc/ LSC recipients (red). p = 0.1757, Student’s t test; n = 11–17 from two independent experiments.
(D and E) Time-course analysis of GFP+ engraftment of WT and Terc/ secondary recipients injected with 100 (blue), 1,000 (purple), 10,000 (red), 100,000 (black)
BM-derived AML (mean ± SE, n = 5).
(F–I) Representative flow cytometry and quantification (F) of cell cycle of LSCs in G0 (G), G1 (H), and S/G2/M (I); n = 16–17.
(J and K) Representative flow cytometric analysis (J) and quantification (K) of gamma-H2AX in diploid WT (black) or Terc/ (red) LSCs; n = 16–17.
(L and M) Representative apoptosis flow cytometry (GFP+LinKithighannexinV+; L) and quantification of apoptotic LSCs (M) in BM; n = 16–17. All cell-fate
experiments are from three independent experiments. Each point represents an individual biological replicate, and significance was determined with a Student’s
t test.
See also Figure S5.
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Telomerase Is a Target for Leukemia Stem Cellstreatment effectively prevented in vivo expansion of this
sample (Figure 7K). Next, we examined a patient derived
xenograft sample (AML-5) with complex cytogenetics (predict-
ing a dismal clinical outcome). Even in this sample, imetelstat
prevented AML expansion, although, in this case, there wasCellno observed depletion in immunophenotypic LSCs or delay in
disease relapse after transplantation (Figures S7G–S7J). Inter-
estingly, the AML patient sample with the highest sensitivity to
imetelstat in vivo (i.e., AML-X) showed enrichment for the
Terc/ LSC gene expression signature (Figure S7K). PrincipalStem Cell 15, 775–790, December 4, 2014 ª2014 Elsevier Inc. 783
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Figure 6. A Telomerase-Regulated Gene Signature Identifies a Cohort of Human AML with Adverse Clinical Prognosis
(A) In silico analysis of TERT expression levels in human AML and purified hematopoietic cells (http://servers.binf.ku.dk/hemaexplorer/).
(B) Hierarchical clustering analysis of AML patients by the Terc signature (top 140 genes differentially regulated between Terc/ and WT LSCs according to
p value). Heatmap showing expression intensities of the probesets in the Bullinger data set. Blue denotes low expression intensity, and red shows high expression
intensity.
(C) Survival analysis of the Bullinger data set of the five classes determined by hierarchical clustering analysis by the Terc signature.
(legend continued on next page)
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Telomerase Is a Target for Leukemia Stem Cellscomponent analysis based on the Terc/ LSC gene expression
signature clustered individual AML patients together and sepa-
rated AML-X furthest away from the least sensitive sample,
AML-5 (Figure S7L).
Finally, we tested whether imetelstat could impair disease
relapse after chemotherapy, a highly clinically relevant model
of LSC function. Transplanted recipient mice were treated with
doxorubicin chemotherapy, imetelstat, a combination of imetel-
stat and chemotherapy, or vehicle control. Chemotherapy alone
caused a striking depletion in AML cells initially; however, there
was rapid relapse and expansion of the residual hCD45+ AML
cells (Figures 7L–7N). In contrast, chemotherapy combined
with imetelstat impaired hCD45+ cell expansion in recipient
mice, an effect that was more pronounced than treatment with
imetelstat alone (Figure 7L–7N). No significant hematological
toxicity was seen in blood counts fromNSGSmice during imetel-
stat treatment (Figures S7M–S7O).
These data demonstrate the efficacy of pharmacologic inhibi-
tion of telomerase using imetelstat in human AML to delay or pre-
vent relapse by targeting AML stem cells in vivo. Together, these
data reveal a requirement for telomerase in murine and human
LSC function and identify telomerase as a tractable therapeutic
target in human AML.
DISCUSSION
LSCs represent an elusive, yet critical, therapeutic target for the
improved survival of patients and long-term eradication of AML.
LSCs possess virtually unlimited self-renewal capacity, evi-
denced by the ability to be propagated inexhaustibly in mice dur-
ing serial transplantation (Hope et al., 2004). Using syngeneic
murine AML models, human cell lines, and primary human
AML samples, we showed that AML LSCs require telomerase
for self-renewal and AML maintenance in vivo.
In murine models of AML, genetic deletion of the RNA compo-
nent of the telomerase complex (Terc) resulted in the loss of
in vitro and in vivo self-renewal, best exemplified by a markedly
reduced LSC frequency and the failure of in vivo AML expansion.
This LSC depletion was mediated by telomere shortening
and enforced replicative stress through serial transplantation,
leading to genetic instability, cell-cycle arrest, and massive
apoptosis. LSCs proliferate slowly (Ishikawa et al., 2007), and
it is believed that restricted cell-cycle activity allowing DNA
damage response is essential for AML maintenance and the
prevention of LSC self-renewal exhaustion (Viale et al., 2009).(D) Cytogenetic analysis within the gene set clusters from the Bullinger data set.
(E) Survival analysis of these clusters within the Metzeler data set (cytogenetical
(F) Hazard ratios in theMetzeler data set of the five genes that had been identified
into AML patient groups with either high expression intensities of the probe set of
the probe set of interest within the total population (red symbols) or low expressi
heatmap on the right displays the corresponding directionality of regulation of th
(G) Analysis of MM6-transduced and stably selected for the expression of tw
or scrambled (SCR) controls. Mean ± SE of three biological replicates.
(H) Engraftment of MM6 in NSGS peripheral blood (human CD45 at 47 day
NT = nontransduced control; n = 5 (NT and shTERT) or 3 (SCR).
(I) Quantification of apoptotic MM6 (mean ± SE, nR 3).
(J) Survival analysis of NSGS injected with 10,000 viable MM6 from each NT, SCR
from two independent experiments.
See also Figure S6.
CellInterestingly, the detrimental effects of telomerase loss were
most evident in LSCs, as demonstrated by a progressive in-
crease in the effect on self-renewal during serial passaging
in vitro and serial transplantation in vivo.
The maintenance of an immature LSC population correlates
strongly with LSC function (Sykes et al., 2011; Wang et al.,
2010). Differentiation and apoptosis are induced in telomerase-
deficient Kit+ LSC populations, suggesting that these pathways
are common mediators of LSC depletion. Moreover, the en-
forced differentiation of Terc/ LSCs is consistent with a previ-
ous study in which DNA damage mediated by gamma irradiation
or telomerase deficiency induced adult stem cell differentiation,
thereby limiting self-renewal (Wang et al., 2012). Altogether,
these data provide strong mechanistic evidence that telomerase
deficiency depletes LSCs via the DNA damage and differentia-
tion and apoptosis cascade.
Importantly, these results were validated in human AML using
both AML cell lines and primary human AML samples. Genetic
knockdown of the enzymatic subunit of telomerase (hTERT) de-
layed leukemia onset in the MM6 xenograft model, resulting in
improved survival. Consistent with the primary murine data, the
in vivo expansion of hTERT knockdown MM6 cells was limited
by the induction of apoptosis. Therefore, we tested the response
of mice engrafted with primary human AML cells to treatment
with the antisense oligonucleotide telomerase inhibitor imetel-
stat. Strikingly, treatment with imetelstat prevented the in vivo
expansion of AML cells, and this was sustained during treat-
ment. Although the AML was not fully eradicated by this therapy,
the in vivo proliferation was controlled, raising the possibility
that telomerase inhibition may be used to prolong remission by
preventing LSC expansion and hence clinical relapse. These
findings are of direct and immediate clinical relevance, given
that imetelstat has entered early phase clinical trials for a number
of malignancies.
To further investigate themechanism of LSC loss after telome-
rase deletion, gene expression analysis revealed widespread
transcriptional changes involving DNA damage repair pathways,
homologous recombination, and cell death. Unlike others (Bernt
et al., 2011; Dawson et al., 2011; Zuber et al., 2011), we did not
observe any loss of the MLL-fusion gene expression signature,
suggesting that MLL-AF9 binding to target genes is not affected
by telomerase loss. In contrast, activation of p53 was predicted
in functionally impaired Terc/ LSCs. Genetic depletion of p53
rescued some of the effects of telomere loss, most notably LSC
apoptosis and enforced differentiation. However, p53 depletionly normal samples).
by random forest modeling in the Bullinger data set. The populationwas divided
interest (deviating at least by log2 > 1 from the average expression intensity of
on intensities (log2 < 1 from average expression intensity blue symbols). The
e respective gene in the murine model (Terc/ LSC versus WT LSC).
o different shRNA constructs targeting TERT (shTERT#466 or shTERT#794)
s posttransplant). Each point represents an individual biological replicate.
, shTERT#466, or shTERT#795 condition; n = 6. All cell line data were collected
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Figure 7. Pharmacological Targeting of Telomerase Impairs Human AML LSC Function and Prolongs Survival in Primary AML Xenografts
(A and B) Donor chimerism (hCD45%; A) and survival analysis (B) of tertiary human MLL-AF9 AML patient (AML-X):NSGS transplants treated with telomerase
inhibitor imetelstat or vehicle control; n = 9 from two independent experiments. Statistical differences in survival were calculated by Mantel-Cox test.
(C–E) Expansion of AML patient samplesmeasured in the PB of normal cytogenetics AMLwith FLT3-ITD (AML-16; C), complex cytogenetics subtype (AML-5; D),
and MLL-AF9 AML (AML-18; E) xenografts. Mean ± SE, n = 6.
(legend continued on next page)
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Telomerase Is a Target for Leukemia Stem Cellswas insufficient to completely rescue LSC function, suggesting
that other pathways cooperate in order to constrain AML LSCs
in telomerase-deficient cells. The p53 pathway is required for
chemotherapy sensitivity (Zuber et al., 2009), and TP53 is
mutated in many complex karyotype AML patients, leading to
chemotherapy resistance and poor prognosis (Cancer Genome
Atlas Research Network, 2013; Ru¨cker et al., 2012). Telomerase
inhibition may retain some function even in p53 mutated AML
due to the additional p53-independent effects of telomerase
deficiency.
Telomerase is also active and required for long-term HSC
function. Early-generation telomerase deficient mice can
engraft and repopulate lethally irradiated recipients; however,
this function is lost after the third round of transplantation (All-
sopp et al., 2003). Moreover, late-generation (G4/G5), telome-
rase-deficient mice have critically shortened telomeres, loss of
HSCs, and premature aging (Blasco et al., 1997). We used G3
telomerase-deficient mice in which telomeres are shortened
and have minimal phenotypic aberrations. These mice showed
relative preservation of LT-HSC frequency and quantitative
but stable reduction in LT-HSC function. These data are consis-
tent with other reports demonstrating that HSCs from G3 telo-
merase-deficient mice have a quantitative reduction in function
(Choudhury et al., 2007). These studies raise legitimate con-
cerns about the effective therapeutic window of telomerase
inhibitors; however, it should be noted that most existing AML
chemotherapy regimens are limited by severe myelosuppres-
sion particularly in elderly patients. The effects of telomerase in-
hibitors on DNA damage repair pathways may also predispose
to leukemogenesis or secondary malignancies; however, given
the dismal long-term survival in elderly AML patients, there is
an urgent need to test novel, highly effective therapies in these
patients. Notably, in the xenograft transplantation experiments,
we did not observe hematological toxicity of imetelstat-treated
mice in comparison to controls. Only properly conceived and
designed clinical trials with long-term follow up can accurately
determine the efficacy and tolerability of these compounds in
AML patients.
Interestingly, we identified a telomerase-related gene expres-
sion signature that reproducibly clustered primary human AML
samples into discrete groups. Most importantly, this signature
identified a poor prognostic subgroup of patients with AML.
Correlation analysis revealed five genes (SMC4, CPD, MRC1,
SLC2A1, and SLC44A2) with the most powerful impact on sur-
vival and provocatively, these genes were all located within a
pathway controlling DNA damage and repair. Three out of the
five genes identified represent annotated c-MYC target genes
(i.e., MRC1, CPD, and SLC2A1). C-MYC is a proto-oncogene,(F) Splenic infiltration of AML for AML-16, AML-5, and AML-18; n = 6.
(G) G0 cell-cycle flow cytometry of CD45+ cells from AML-16, AML-18, and CD4
(H) Example CD34/CD38 flow plot on splenic cells from imetelstat or vehicle-trea
(I and J) CD38low (I) and CD38high (J) AML cells; n = 6.
(K) Secondary transplant of hCD45+ cells from imetelstat (blue) or vehicle-treat
treated with imetelstat (red or purple, respectively). *p < 0.05; **p < 0.01; ***p < 0
(L–N) Donor chimerism analysis of AML-16 (L), AML-18 (M), and AML-5:NSGS (N
(red), doxorubicin and vehicle control (blue), or doxorubicin in combination with im
from three biologically independent samples. *p < 0.05; **p < 0.01; ***p < 0.001; ***
unless stated otherwise.
See also Figure S7 and Table S1.
Celland its role in tumor cell biology has been extensively investi-
gated. Two recent papers used novel bromodomain inhibitors
as potent therapies against MLL-rearranged AML, and the inhi-
bition of Myc targets is proposed as a key component of this
therapeutic success (Dawson et al., 2011; Zuber et al., 2011).
Furthermore, Smc4 is a member of the cohesin family of genes
that are recurrently mutated in human AML, although the func-
tional role of abnormal cohesin expression or mutations in AML
remains unknown (Cancer Genome Atlas Research Network,
2013). Altogether, these data suggest that the regulation of
DNA repair pathways within LSCs may also govern response
to AML treatment.
In conclusion, modulation of the telomerase complex is a high-
ly effective strategy for targeting LSCs in AML. Clinical trials
should address the efficacy of telomerase inhibitors such as im-
etelstat as a consolidation strategy for preventing relapse or
potentially together with chemotherapy to improve outcomes
in AML patients.
EXPERIMENTAL PROCEDURES
Plasmids
The MSCV-MLL-AF9-GFP and MSCV-MLL-AF9-neo constructs were previ-
ously described (Lane et al., 2011). The v2luc construct was a gift from Dr.
M. Milsom. MSCV-NUP98-HOXA9, MSCV-BCR-ABL, and MSCV-AML1ETO
were obtained from Dr. D.G. Gilliland. MSCV-KRasG12C and MSCV-CDX2
were obtained from Dr. S. Fro¨hling and Dr. C. Scholl. The lmp.sh-P53 and
lmp.sh-luc constructs were a gift from Dr. Ross Dickins.
Mouse Models
Terc/ mice were obtained from Jackson Laboratories and were maintained
on C57Bl/6J background (http://jaxmice.jax.org/strain/004132.html). The third
generation of homozygous (G3 Terc/) were used. C57Bl/6J recipient mice
were purchased from Animal Resources Centre, Australia. NSGS mice (i.e.,
NOD.Cg-Prkdcscid Il2rgtm1Wjl Tg[CMV-IL3,CSF2,KITLG]1Eav/MloySzJ) were
imported from Jackson Laboratories. All mice were kept pathogen-free in
the animal facility of QIMR Berghofer Medical Research Institute. NSGS
mice received autoclaved and Baytril-treated (Provet) water. All mouse exper-
iments were approved by the institutional ethics committee protocol
A11605M.
Fluorescence-Activated Cell Sorting and Analysis
LKS+ populations were purified from BM after red blood cell lysis (BD Pharm-
lyse, BD Biosciences) and was stained with a lineage cocktail comprising
of Cd3e (145-2C11), Cd5 (53-7.3), Ter119 (TER-119), Gr-1 (RB6-8C5),
B220 (RA3-6B2), and Mac-1 (M1/70), lineage-depleted with biotin-binder
Dynabeads (Invitrogen) and stained with streptavidin-ApcCy7, Kit (2B8), and
Sca-1 (D7). LSCswere isolated fromBMafter RBC lysis and stained with a bio-
tinylated lineage cocktail containing Gr-1 (RB6-8C5), Ter119 (TER-119), B220
(RA3-6B2), Cd3e (145-2C11), Cd5 (53-7.3), and Sca-1 (D7) and subsequently
with streptavidin, Kit (2B8), Cd16/Cd32 (93), and Cd34 (RAM34). Cells were
sorted with a FACSAria instrument (Becton Dickinson).5+CD34+ cells from AML-5:NSGS xenografts. n = 6. p = 0.0002.
ted AML-16:NSGS xenografts.
ed (black) primary AML-16:NSGS xenografts. The secondary recipients were
.001.
) xenografts treated with vehicle controls (black), imetelstat and vehicle control
etelstat (purple) during the early and late progression phases of AML; n = 5–6
*p < 0.0001. All statistical significances were determined with a Student’s t test
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sciences). Postacquisition analyses were performed with FlowJo software
V9.2.3 (Tree Star). For live-dead cell discrimination, Sytox blue (Invitrogen)
was used.
For cell-cycle and DNA damage analysis, cells were fixed and permeabilized
(Fix & Perm, GAS-004; Invitrogen) according to themanufacturer’s instructions
and incubated with Ki-67 (B56) and gH2AX (20E3; Cell Signaling Technology).
Hoechst 33342 (Invitrogen) was used at 20 mg/ml in PBS containing 2% fetal
bovine serum.
For apoptosis analysis, cells were stained with Annexin V (BD Biosciences)
in Annexin V binding buffer according to the manufacturer’s recommendations.
MLL-AF9 Retroviral BM Transplantation Assay
Purified LKS+ populations were transduced with MLL-AF9-GFP or MLL-AF9-
neo containing retrovirus and transplanted into 5.5 Gy irradiatedWT recipients
via lateral tail vein. For serial transplantation assay, BM or splenic GFP+ cells
were injected into irradiated WT recipients. Mice were monitored for external
(hunched posture, reduced movement, and ruffled fur) and internal (WCC)
signs of leukemia. For homing assay, 13 106 cells were injected per recipient,
and BM was analyzed 16 hr posttransplant.
Blood Analysis
Blood was collected into EDTA-coated tubes and analyzed on a Hemavet 950
analyzer (Drew Scientific). PB smears were stained with Wright-Giemsa stain-
ing according to the manufacturer’s protocol (BioScientific).
Colony-Forming Assay
Transformed LKS+ were plated in M3434 cytokine-enriched methylcellulose
(STEMCELL Technologies), counted, and passaged after 5–7 days.
Histology
Tissueswere fixed in 10%neutral buffered formalin, embedded in paraffin, and
stained with H&E. Images of histological slides were obtained on a ScanScope
FL (Aperio).
Cell Culture
MM6 cell line was obtained from Dr. S. Fro¨hling. Cells were cultured in RPMI
supplemented with 10% fetal calf serum, 2 mM glutamine, 200 U/ml penicillin,
200 ug/ml streptomycin, 23 nonessential amino acids, and 5 ml OPI supple-
ment (Sigma-Aldrich) per 500 ml medium.
In Vitro Cell-Growth Analysis
For in vitro cell-growth analysis, MM6 cells were seeded into a 96-well plate
at a density of 2,500 cells per 100 ul final volume. Cells were analyzed with
Celltiter 96 aqueous nonradioactive cell proliferation assay (MTS Systems)
according to the manufacturer’s instructions (Promega).
Gene Expression Profiling and Bioinformatics Analysis
WT and G3 Terc/ MLL-AF9 LSC were purified from primary recipients
at AML onset. RNA was extracted with a QIAGEN RNeasy Micro Kit, preampli-
fied with the Illumina TotalPrep RNA Amplification Kit, and hybridized on
Illumina MouseWG-6 v2 BeadChip array. The data were imported with
IDATreader (http://www.compbio.group.cam.ac.uk/software/idatreader) to R
from Illumina GenomeStudio after default trimming and collapsing of
beads. The data were normalized with lumi (Du et al., 2008). Probes were re-
annotated as described previously (Barbosa-Morais et al., 2010) (version
mm9_V1.0.0_Aug09) and filtered for poor or unspecific probes as described
previously (Ritchie et al., 2011). Human homologs were acquired with Homo-
loGene (http://www.ncbi.nlm.nih.gov/homologene, build 67). Unsupervised
Hierarchical clustering was performed in R with a Hartigan-Wong algorithm
(Hartigan and Wong, 1979) with ten random starts for robust clustering.
Random survival forest models were built with censored and uncensored sur-
vival observations (Ishwaran and Kogalur, 2010). Importance was assessed by
permutation and the forest contained 20,000 trees.
Xenograft Transplantation Experiments
Primary AML samples were obtained from patients with AML, after informed
consent in accordance with the Declaration of Helsinki. Ficoll density gradient788 Cell Stem Cell 15, 775–790, December 4, 2014 ª2014 Elsevier Inwas then used to recover viable mononuclear cells. MM6 cells or primary hu-
man AML cells were injected via the lateral tail vein into 2.4 Gy irradiated NSGS
recipients.
Drug-Treatment Studies
NSGS mice were treated with 15 mg/kg imetelstat or vehicle control via the
intraperitoneal route for the period of time specified in the respective experi-
ment. For chemotherapy studies, doxorubicin (1.5 mg/kg) was administered
intravenously for 3 consecutive days starting from 24 hr posttransplant in strict
24 hr intervals, and nonirradiated recipients were used. For chemotherapy plus
imetelstat combination studies, the first imetelstat injection was administrated
on day 3 posttransplant directly after doxorubicin injection. Human AML cell
engraftment wasmonitored by staining of PBwith human-specific CD45 stain-
ing (H130) against mouse CD45.1 and subsequent flow cytometric analysis on
LSR Fortessa (BD Biosciences).
Statistical Analysis
A log-rank (Mantel-Cox) test was used to determine p values for all Kaplan-Me-
ier survival analyses. An unpaired two-tailed Student’s t test was used for all
analyses comparing two experimental groups. Poisson statistics were used
to determine LSC frequencies in the limiting dilution experiments.
ACCESSION NUMBERS
The microarray data set has been deposited to the NCBI Gene Expression
Omnibus under accession number GSE63241.
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